Mar 31, 2025 4:30 pm EDT OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
Mar 31, 2025 7:40 am EDT OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
Mar 25, 2025 7:40 am EDT OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Mar 21, 2025 7:40 am EDT OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
Mar 13, 2025 7:40 am EDT OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
Mar 11, 2025 7:40 am EDT OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
Feb 26, 2025 4:01 pm EST Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
Feb 24, 2025 7:25 am EST OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Feb 20, 2025 5:00 am EST OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2